|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/ESCMID_Awards_calls_636x318.jpg) |
The ESCMID awards season is coming soon
|
In celebration of excellence and innovation in Clinical Microbiology (CM) and Infectious Diseases (ID), ESCMID honours the contributions made by researchers, clinicians, and other trailblazers in these fields. Distinguished awardees have the opportunity to deliver lectures at ESCMID Global and may even join the esteemed ranks of ESCMID Fellows.
You can check out on our website all the awards offered by the society and past awardees to get inspiration. Stay tuned!
|
|
|
|
|
|
|
|
|
|
Science & Research
|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/Call_for_Study_Group_research_grants_588x294.jpg) |
|
Apply for Study Group Research Grant – call open until 19 July 2024
|
Dive into cutting-edge research with ESCMID SG research grants, tailored for CM and ID related projects. Our SGs cover a vast range of themes, ensuring that there are no limits on the topics eligible for funding each year. With up to 30K EUR offered to cover project costs, ESCMID SG research grants can help you support the entirety or specific elements of your project.
Deadline for applications is on 19 July 2024.
|
|
|
Education
|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/ESCMID_Courses_Athens_588x294.jpg) |
|
Join this onsite course in Athens, Greece, from 25-27 September 2024
|
This dynamic course features eight sessions on cutting-edge topics, including precision antimicrobial treatment, combating resistance, and innovative sepsis classification. Learn to recognise sepsis early, explore new immunotherapies, and utilise biomarkers for accurate diagnostics. Enhance your skills in treating multidrug-resistant pathogens and designing impactful research. Join us to transform your approach to sepsis management and improve patient outcomes.
Registration is open until 1 September 2024.
|
|
|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/ESCMID_Courses_Bertinoro2_588x294.jpg) |
|
Join this onsite course in Bertinoro, Italy, from 22-26 September 2024
|
Through a mix of lectures, clinical case presentations by experts in the field and interactive group discussions, this course will provide updated information on epidemiology and burden of infectious diseases in pregnancy and newborns as well as collaborative diagnostic and clinical pathways for the management of these infections. It will also cover pathogenesis of fetal and neonatal damages and pre- and postnatal counselling.
Registration is open until 23 August 2024.
|
|
|
Congress & Events
|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/Towards_ESCMID_Global_2025_588x294.jpg) |
New YouTube series coming: Towards ESCMID Global 2025
|
A new video series is coming to the ESCMID YouTube Channel at the end of this week. The ESCMID Global Programme Committee came together in Prague to work on the scientific programme for the upcoming ESCMID Global 2025 in Vienna. We sat down with a few members to get their impressions on the programme so far and what we can expect to see at next year’s event. The first episode will drop this weekend so be sure to check out the channel and catch up on any videos you missed so far.
|
|
|
Guidelines & Journals
|
![Hero Image Image](https://newsletter.escmid.org/weekly/2024/20240702/CMI_Communications_podcast2b_588x294.jpg) |
|
Listen to the fourth episode of the CMI Communications podcast
|
Big news from a recent clinical trial are discussed in the fourth episode of CMI Comms monthly podcast Communicable: “The BLING-3 trial & continuous beta-lactam infusion: should these results change your practice?”, featuring co-hosts Angela Huttner and Erin McCreary. Guests are trial investigators Josh Davis and David Paterson. The podcast is available for all major platforms. More details can be found on the ESCMID website.
|
|
|
|
|
![Logo Registration](https://newsletter.escmid.org/weekly/2024/20240702/CMI_Logo_588x70.jpg) |
Advances and Prospect in Herpesviruses infections after Hematopoietic Cell Transplantation: Closer to the Finish Line?
|
|
|
|
|
|